Elevance Health, Inc. ELV
Nov 6, 2026, 1:19 PM EST
- YTD
- +22.41%
- 1 year
- +36.47%
- Market cap
- 92.69B
- Revenue (ttm)
- 201.83B
- Profit margin
- 2.55%
- EPS (ttm)
- 23.55
- Shares out
- 216.87M
- P/E ratio
- 18.22
- Forward P/E
- 14.34
- Dividend
- 6.88 (1.66%)
- Ex-dividend date
- Dec 3, 2026
- YTD return
- +22.41%
- 1-year return
- +36.47%
- Volume
- 498.66K
- Avg volume
- 1.20M
- Open
- 421.47
- Previous close
- 432.00
- Day's range
- 421.72 – 429.78
- 52-week range
- 280.74 – 445.28
- Beta
- 0.63
- Analysts
- Buy
- Price target
- 482.38 (+12.4%)
- Earnings date
- Jan 27, 2027
3M +35.10 (+8.90%)
Key statistics
- Enterprise value
- 82.42B
- PEG ratio
- 1.27
- Price / sales
- 0.47
- Price / book
- 2.10
- Dividend yield
- 1.66%
- Payout ratio
- 29.17%
- Revenue growth
- 1.40%
- Free cash flow
- 7.99B
- Total cash
- 37.85B
- Total debt
- 30.76B
- Return on equity
- 11.48%
- Short % of float
- 2.65%
- 50-day average
- 411.05
- 200-day average
- 372.70
Analyst view
Consensus: buy
- Target (low)
- 406.00
- Target (mean)
- 482.38
- Target (high)
- 523.00
- Strong buy3
- Buy12
- Hold7
- Sell0
- Strong sell0
Next earnings
Jan 27, 2027
Expected Jan 27, 2027. Consensus EPS estimate 2.07.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 27, 2027 | Dec 30, 2026 | 2.08 | — | — | — |
| Oct 21, 2026 | Sep 30, 2026 | 4.71 | 6.99 | +2.28 | +48.41% |
| Jul 15, 2026 | Jun 30, 2026 | 6.21 | 7.45 | +1.24 | +19.97% |
| Apr 22, 2026 | Mar 31, 2026 | 10.82 | 12.58 | +1.76 | +16.27% |
| Jan 28, 2026 | Dec 31, 2025 | 3.10 | 3.33 | +0.23 | +7.42% |
| Oct 21, 2025 | Sep 30, 2025 | 4.93 | 6.03 | +1.10 | +22.31% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 23, 2026 | TD Cowen | main | Buy | Buy |
| Oct 22, 2026 | UBS | main | Buy | Buy |
| Oct 22, 2026 | Guggenheim | main | Buy | Buy |
| Oct 22, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 22, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
About Elevance Health, Inc.
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Healthcare Plans
- Country
- United States
- Website
- elevancehealth.com
News
CVS Tumbles 12% on Plan to Split Into Two Companies Despite Earnings Beat; Elevance Health Rises 4%, Cigna Climbs 3% 
Elevance Health (ELV) Is Up 2.73% in One Week: What You Should Know 
Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492 
10 Health Care Stocks Whale Activity In Today’s Session 
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495 
UBS Maintains Buy on Elevance Health, Raises Price Target to $523 
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485 
Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449 - RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455
- Barclays Maintains Overweight on Elevance Health, Raises Price Target to $472
Your note
Sign in to keep a note on ELV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOUDREAUX GAIL A KOZIARA | Chief Executive Officer | Purchase | Jul 16, 2026 | 172,036 |
| BOUDREAUX GAIL KOZIARA | Chief Executive Officer | Stock Award(Grant) | Mar 1, 2026 | 169,311 |
| DIXON ROBERT L JR | Director | Sale | Jun 10, 2026 | 10,734 |
| HAY LEWIS III | Director | Stock Award(Grant) | May 12, 2026 | 12,070 |
| HAYTAIAN PETER D | Officer | Stock Award(Grant) | Mar 1, 2026 | 27,222 |
| KAYE MARK | Chief Financial Officer | Stock Award(Grant) | Oct 1, 2026 | 30,503 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.79% | 18,991,090 | 8.25B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.51% | 14,058,204 | 6.10B | Jun 29, 2026 |
| State Street Corporation | 4.83% | 10,426,610 | 4.53B | Jun 29, 2026 |
| Wellington Management Group, LLP | 4.26% | 9,213,513 | 4.00B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.88% | 6,214,356 | 2.70B | Jun 29, 2026 |
| Sanders Capital, LLC | 2.70% | 5,830,605 | 2.53B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.06% | 6,607,886 | 2.87B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.49% | 5,390,387 | 2.34B | Jun 29, 2026 |
| VANGUARD WINDSOR FUNDS-Vanguard Windsor II Fund | 1.41% | 3,038,771 | 1.32B | Jul 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.34% | 2,889,977 | 1.25B | Sep 29, 2026 |
| First Eagle Funds-First Eagle Global Fund | 1.32% | 2,844,869 | 1.24B | Jul 30, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 2,818,420 | 1.22B | Sep 29, 2026 |